Zai Lab Ltd
$ 17.64
2.20%
11 Jun - close price
- Market Cap 1,954,974,000 USD
- Current Price $ 17.64
- High / Low $ 17.67 / 16.76
- Stock P/E N/A
- Book Value 6.47
- EPS -1.70
- Next Earning Report 2026-08-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.13 %
- ROE -0.24 %
- 52 Week High 42.00
- 52 Week Low 15.96
About
Zai Lab Limited, a biopharmaceutical company, discovers, licenses, develops and markets therapies to treat cancer, autoimmune and infectious diseases in China. The company is headquartered in Shanghai, China.
Analyst Target Price
$33.78
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-07 | 2026-02-26 | 2025-11-06 | 2025-08-07 | 2025-05-08 | 2025-02-27 | 2024-11-12 | 2024-08-06 | 2024-05-08 | 2024-02-27 | 2023-11-07 | 2023-08-07 |
| Reported EPS | -0.46 | -0.46 | -0.33 | -0.37 | -0.45 | -0.8 | -0.42 | -0.82 | -0.5 | -0.98 | -0.71 | -1.25 |
| Estimated EPS | -0.2909 | -0.42 | -0.28 | -0.42 | -0.55 | -0.6333 | -0.78 | -0.73 | -0.92 | -0.87 | -1.03 | -0.81 |
| Surprise | -0.1691 | -0.04 | -0.05 | 0.05 | 0.1 | -0.1667 | 0.36 | -0.09 | 0.42 | -0.11 | 0.32 | -0.44 |
| Surprise Percentage | -58.1299% | -9.5238% | -17.8571% | 11.9048% | 18.1818% | -26.3224% | 46.1538% | -12.3288% | 45.6522% | -12.6437% | 31.068% | -54.321% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-06 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.67 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ZLAB
2026-06-10 15:39:29
Zai Lab (ZLAB) has received approval from China's National Medical Products Administration for TIVDAK to treat advanced cervical cancer, strengthening its oncology portfolio and near-term launch pipeline. This approval gives Zai Lab exclusive commercialization rights in Greater China and is seen as a key catalyst, although the company still faces risks related to pricing, competition, reliance on in-licensed assets, and the need to improve profitability. The article highlights TIVDAK and another drug, zocilurtatug pelitecan (zoci), as central to Zai Lab's investment narrative, with analysts projecting significant revenue and earnings growth by 2029.
2026-06-09 13:10:26
Zai Lab Limited (ZLAB) has received Chinese regulatory approval for its antibody-drug conjugate Tivdak, co-developed with Pfizer and Genmab, for recurrent or metastatic cervical cancer after chemotherapy. This approval follows positive Phase 3 trial results and is expected to boost Zai Lab's market presence given the high incidence of cervical cancer in China. However, investors are advised to exercise caution due to significant insider selling and low profitability metrics, despite the company's strong growth potential.
2026-06-09 12:09:57
Zai Lab has announced that China's National Medical Products Administration (NMPA) has approved TIVDAK® (tisotumab vedotin for injection) for recurrent or metastatic cervical cancer. This approval marks TIVDAK as the first antibody-drug conjugate (ADC) for this indication in China, supported by significant overall survival benefits shown in the global Phase 3 innovaTV 301 clinical trial, including in a Chinese subpopulation. The drug offers a new treatment option for patients with limited therapeutic choices after chemotherapy.
2026-06-09 12:09:37
Zai Lab (NASDAQ:ZLAB) has received approval from China's National Medical Products Administration (NMPA) for its Biologics License Application for TIVDAK, a treatment for recurrent or metastatic cervical cancer. This approval marks TIVDAK as the first antibody-drug conjugate for this indication in China, following positive results from the Phase 3 innovaTV 301 trial which showed a significant overall survival benefit. The drug's efficacy was consistent even in patients previously treated with immunotherapy, addressing a critical need given cervical cancer's prevalence in China.
2026-06-09 07:09:25
Zai Lab (ZLAB) is gaining investor attention following China's approval of TIVDAK for advanced cervical cancer, despite a significant drop in its share price over the past year. The stock is currently valued at $16.48, which is considerably below its narrative fair value of $33.78, suggesting it is undervalued by 51.2%. This valuation disparity is attributed to its strong pipeline of high-potential product launches and label expansions, which are expected to boost revenue and diversify its market presence.
2026-06-09 00:09:25
Zai Lab has announced that China's National Medical Products Administration (NMPA) approved TIVDAK for the treatment of recurrent or metastatic cervical cancer. This approval is based on global Phase 3 trial data, including a China subpopulation, which showed significant overall survival benefits and a 45% reduction in the risk of death compared to chemotherapy. TIVDAK is an antibody-drug conjugate and is now approved in multiple regions globally, offering a new treatment option for patients with limited therapeutic choices.
